Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors

뉴스 본문을 불러오고 있어요.

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors | 웨이프 WAPE

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors

기사 요약

관련 종목

댓글 —